Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE19.9500
- TODAY'S CHANGE (%)-0.1700 (-0.8449%)
- Bid / Lots19.9500/ 2
- Ask / Lots19.9600/ 2
- Open / Previous Close19.9500 / 20.1200
- Day Range
- 52 Week Range
- Volume174,925
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 1130 | 19.95 |
| 09:37 ET | 100 | 19.995 |
| 09:39 ET | 100 | 20.195 |
| 09:48 ET | 400 | 20.255 |
| 09:50 ET | 700 | 20.22 |
| 09:51 ET | 1270 | 20 |
| 09:53 ET | 2978 | 20.01 |
| 09:55 ET | 2500 | 20.075 |
| 10:00 ET | 1400 | 20.01 |
| 10:02 ET | 500 | 20 |
| 10:06 ET | 200 | 20 |
| 10:08 ET | 100 | 20 |
| 10:09 ET | 600 | 19.9 |
| 10:11 ET | 300 | 20.01 |
| 10:13 ET | 900 | 20 |
| 10:15 ET | 1126 | 19.935 |
| 10:20 ET | 200 | 20 |
| 10:22 ET | 400 | 19.95 |
| 10:24 ET | 100 | 19.955 |
| 10:27 ET | 100 | 19.92 |
| 10:36 ET | 100 | 19.95 |
| 10:38 ET | 25452 | 20.17 |
| 10:40 ET | 100 | 20.225 |
| 10:42 ET | 14815 | 20.255 |
| 10:44 ET | 200 | 20.3099 |
| 10:47 ET | 500 | 20.41 |
| 10:51 ET | 700 | 20.36 |
| 10:56 ET | 200 | 20.34 |
| 10:58 ET | 790 | 20.2 |
| 11:02 ET | 100 | 20.15 |
| 11:03 ET | 100 | 20.175 |
| 11:12 ET | 100 | 20.14 |
| 11:14 ET | 238 | 20.16 |
| 11:18 ET | 100 | 20.16 |
| 11:21 ET | 100 | 20.175 |
| 11:23 ET | 100 | 20.21 |
| 11:25 ET | 327 | 20.235 |
| 11:27 ET | 300 | 20.3 |
| 11:32 ET | 100 | 20.31 |
| 11:36 ET | 100 | 20.42 |
| 11:41 ET | 100 | 20.36 |
| 11:45 ET | 1500 | 20.47 |
| 11:48 ET | 1202 | 20.485 |
| 11:50 ET | 100 | 20.53 |
| 11:52 ET | 3177 | 20.25 |
| 11:54 ET | 100 | 20.2 |
| 11:56 ET | 388 | 20.2 |
| 11:57 ET | 336 | 20.14 |
| 11:59 ET | 100 | 20.08 |
| 12:03 ET | 300 | 20.06 |
| 12:08 ET | 400 | 20.11 |
| 12:12 ET | 100 | 20.21 |
| 12:14 ET | 100 | 20.12 |
| 12:19 ET | 100 | 20.115 |
| 12:24 ET | 6182 | 19.99 |
| 12:28 ET | 200 | 19.99 |
| 12:30 ET | 1500 | 20.05 |
| 12:32 ET | 117 | 20.08 |
| 12:33 ET | 100 | 20.12 |
| 12:37 ET | 180 | 20.085 |
| 12:39 ET | 100 | 20.11 |
| 12:42 ET | 100 | 20.07 |
| 12:44 ET | 100 | 20.06 |
| 12:48 ET | 200 | 20.09 |
| 12:50 ET | 600 | 20.11 |
| 12:51 ET | 100 | 20.11 |
| 12:55 ET | 100 | 20.17 |
| 01:00 ET | 1735 | 20.065 |
| 01:02 ET | 100 | 20.1 |
| 01:04 ET | 100 | 20.06 |
| 01:11 ET | 2176 | 19.98 |
| 01:13 ET | 200 | 20 |
| 01:15 ET | 400 | 19.99 |
| 01:18 ET | 200 | 19.995 |
| 01:20 ET | 4201 | 20.0466 |
| 01:27 ET | 20200 | 20.02 |
| 01:29 ET | 223 | 20.05 |
| 01:31 ET | 500 | 20.06 |
| 01:33 ET | 100 | 20.06 |
| 01:36 ET | 225 | 20.14 |
| 01:38 ET | 100 | 20.14 |
| 01:40 ET | 600 | 20.11 |
| 01:42 ET | 1010 | 20.1 |
| 01:44 ET | 100 | 20.08 |
| 01:51 ET | 200 | 20.1 |
| 01:54 ET | 500 | 20.065 |
| 01:56 ET | 300 | 20 |
| 01:58 ET | 200 | 20.02 |
| 02:00 ET | 100 | 20 |
| 02:02 ET | 873 | 20.01 |
| 02:16 ET | 400 | 20.03 |
| 02:18 ET | 100 | 20.01 |
| 02:20 ET | 948 | 20.03 |
| 02:21 ET | 200 | 20.05 |
| 02:23 ET | 100 | 20.11 |
| 02:30 ET | 1100 | 20.1096 |
| 02:32 ET | 400 | 20.1 |
| 02:34 ET | 700 | 20.075 |
| 02:36 ET | 1600 | 20.05 |
| 02:38 ET | 400 | 20.04 |
| 02:41 ET | 300 | 20 |
| 02:43 ET | 500 | 19.995 |
| 02:48 ET | 728 | 20 |
| 02:50 ET | 200 | 20.015 |
| 02:52 ET | 400 | 19.985 |
| 02:56 ET | 100 | 19.985 |
| 02:57 ET | 200 | 20 |
| 02:59 ET | 700 | 19.97 |
| 03:01 ET | 200 | 19.955 |
| 03:03 ET | 200 | 19.89 |
| 03:10 ET | 200 | 19.96 |
| 03:12 ET | 100 | 19.965 |
| 03:14 ET | 316 | 20 |
| 03:15 ET | 100 | 19.97 |
| 03:24 ET | 1300 | 19.97 |
| 03:26 ET | 300 | 20 |
| 03:28 ET | 595 | 19.97 |
| 03:30 ET | 1000 | 19.935 |
| 03:32 ET | 100 | 19.95 |
| 03:33 ET | 100 | 19.96 |
| 03:37 ET | 400 | 19.945 |
| 03:39 ET | 1500 | 19.92 |
| 03:42 ET | 100 | 19.92 |
| 03:46 ET | 502 | 19.95 |
| 03:48 ET | 600 | 19.935 |
| 03:50 ET | 1141 | 19.93 |
| 03:51 ET | 1406 | 20.005 |
| 03:53 ET | 2360 | 19.95 |
Jan 27, 2023
Insider Sell: Crinetics Pharmaceuticals, from 4:31PM ET on Friday Jan 27, 2023 by MT Newswires
4:31PM ET on Friday Jan 27, 2023 by MT Newswires
Jan 10, 2023
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:48PM ET on Tuesday Jan 10, 2023 by GlobeNewswire
4:48PM ET on Tuesday Jan 10, 2023 by GlobeNewswire
Jan 9, 2023
BRIEF-Crinetics Pharmaceuticals Inc - Phase 2 Trial Of Paltusotine In Carcinoid Syndrome On Track For Topline Data In 2H 2023, from 8:53AM ET on Monday Jan 09, 2023 by Thomson Reuters
8:53AM ET on Monday Jan 09, 2023 by Thomson ReutersCrinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference, from 8:01AM ET on Monday Jan 09, 2023 by GlobeNewswire
8:01AM ET on Monday Jan 09, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 1.1B | -6.7x | --- |
Cogent Biosciences Inc | 1.1B | -6.1x | --- |
IGM Biosciences Inc | 1.1B | -4.2x | --- |
Inhibrx Inc | 1.1B | -8.0x | --- |
NewAmsterdam Pharma Company NV | 1.0B | -61.3x | --- |
Arcutis Biotherapeutics Inc | 996.2M | -2.8x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. It has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5), agonist designed for the treatment of congenital hyperinsulinism (HI). CRN04894 is an investigational, oral, nonpeptide product candidate designed for the treatment of diseases caused by excess adrenocorticotrophic hormone (ACTH), including Cushings disease, congenital adrenal hyperplasia (CAH), and Ectopic ACTH Syndrome (EAS).
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- President, Chief Executive Officer, Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $5.1M |
Shares Outstanding | 53.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-2.99 |
Book Value | $6.97 |
P/E Ratio | -6.7x |
Price/Sales (TTM) | 212.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,961.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
